Finally, we showed that the combination of MLN4924 with Erastin or IKE exhibits a better activity against the growth and survival of breast cancer cells in both in vitro cell-culture setting and in vivo xenograft tumor models, providing a proof-of-concept evidence and sound strategy for effective anticancer therapy by MLN4924 in combination of SLC7A11 inhibitors. Here, SLC7A11 is linked to neoplasm.